The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2024 | Adjuvant chemotherapy in biliary tract cancer post-tumor resection
Olatunji Alese, MD, Emory Winship Cancer Institute, Atlanta, GA, briefly summarizes the outcome of a cohort study determining the effect of adjuvant chemotherapy (AC) in 8091 older adult patients that had underwent resection of biliary tract cancer (BTC). Multivariate analysis indicated that AC did not provide a survival advantage, despite initial findings suggesting otherwise. Dr Alese highlights that further investigation of AC in older patients with BTC is required to effectively identify those that are most likely to benefit from AC. BTS patient stratification may prevent instances of surgery-related toxicity and improve the survival outcomes of patients with BTC. This interview took place at the 2024 American Association for Cancer Research (AACR) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
